CD4 and neoplasm: Multiple previous studies have shown that tumor-specific CD4+FoxP3 Tregs express multiple inhibitory receptors, including PD-1 and TIM3, which likely reduce the capacity of T cells in the tumor microenvironment for proliferation and cytokine production [45].